ASO VISUAL ABSTRACT

ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for *BRAF*-Mutant Resected Stage 3 Melanoma in Medicare Patients

Saam A. Mojtahed, BS¹, Nicole R. Boyer, PhD, MPH², Saieesh A. Rao, BS¹, Thomas F. Gajewski, MD, PhD³, Jennifer Tseng, MD⁴, and Kiran K. Turaga, MD, MPH⁴

¹Pritzker School of Medicine, Division of Biological Sciences, University of Chicago, Chicago, IL; ²Center for Health and the Social Sciences, University of Chicago, Chicago, IL; ³Department of Pathology, Division of Biological Sciences, University of Chicago, Chicago, IL; ⁴Department of Surgery, Division of Biological Sciences, University of Chicago, Chicago, IL

This report describes a cost-effectiveness analysis of adjuvant therapies in the treatment of *BRAF*-mutant stage 3 melanoma for Medicare patients (<https://doi.org/10.1245/s10434-021-10288-4>).

The findings demonstrated that although dabrafenib–trametinib offers the greatest improvement in overall survival, it is not as cost-effective as pembrolizumab.

Presented at the 15th Annual Academic Surgical Congress, 4–6 February 2020, Orlando, FL

© Society of Surgical Oncology 2021

Published Online: 5 August 2021

K. K. Turaga, MD, MPH
 e-mail: Kturaga@gmail.com;
 kturaga@surgery.bsd.uchicago.edu

ACKNOWLEDGMENT This study was supported by the Pritzker School of Medicine Summer Research Program and The University of Chicago Department of Surgery.

DISCLOSURE There are no conflict of interest.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.